Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikolas Bergum has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of α-synuclein overexpression on nigrostriatal transmission

    by Nikolas Bergum, Andrew G. Yee, Robert H. Edwards, Christopher P. Ford

    Accumulation of wild-type α-synuclein in dopamine neurons of the Substantia Nigra pars compacta (SNc) is a pathological hallmark of Parkinson’s disease (PD), which commonly precedes neurodegeneration. Yet how α-synuclein accumulation affects nigrostriatal neurotransmission early in the progression of PD remains poorly understood. In addition to axonal dopamine release, SNc neurons also co-release GABA and glutamate from striatal axon terminals and release dopamine from their somatodendritic region. However, the selective vulnerability of these distinct functions to increased α-synuclein remains largely unexplored. Here, we selectively overexpressed wild-type human α-synuclein in SNc dopamine neurons to examine impacts on nigrostriatal and somatodendritic transmission and correlated these changes to impairments in locomotion. We found that dopamine release in the dorsolateral striatum was robustly reduced, while transmission to postsynaptic medium spiny neurons remained intact. Glutamate co-release from dopamine terminals onto both medium spiny neurons and cholinergic interneurons was selectively impaired, while GABA co-release was unaffected. Conversely, somatodendritic dopamine release within the SNc was completely abolished by α-synuclein overexpression. Together, these findings identify selective deficits in nigrostriatal neurotransmission associated with wild-type α-synuclein accumulation prior to overt degeneration and raise the possibility of compensatory adaptations shaping the early functional consequences of α-synuclein pathology in PD.

  • Dopamine enhances GABAA receptor-mediated current amplitude in a subset of intrinsically photosensitive retinal ganglion cells

    by Nikolas Bergum, Casey-Tyler Berezin, Jozsef Vigh

    Neuromodulators such as dopamine are important regulators of retinal function. Here, we demonstrate that dopamine increases inhibitory inputs to intrinsically photosensitive retinal ganglion cells (ipRGCs), in addition to its previously established effect on intrinsic light responsiveness. This indicates that dopamine, in addition to its ability to intrinsically modulate ipRGC activity, can also affect synaptic inputs to ipRGCs, thereby tuning retina circuits involved in nonimage-forming visual functions.


  • Open Access

    Dopamine enhances GABA A receptor-mediated current amplitude in a subset of intrinsically photosensitive retinal ganglion cells

    by Nikolas Bergum, Casey-Tyler Berezin, Jozsef Vigh

    Neuromodulation in the retina is crucial for effective processing of retinal signal at different levels of illuminance. Intrinsically photosensitive retinal ganglion cells (ipRGCs), the neurons that drive non-image forming visual functions, express a variety of neuromodulatory receptors that tune intrinsic excitability as well as synaptic inputs. Past research has examined actions of neuromodulators on light responsiveness of ipRGCs, but less is known about how neuromodulation affects synaptic currents in ipRGCs. To better understand how neuromodulators affect synaptic processing in ipRGC, we examine actions of opioid and dopamine agonists have on inhibitory synaptic currents in ipRGCs. Although µ-opioid receptor (MOR) activation had no effect on γ-aminobutyric acid (GABA) currents, dopamine (via the D1R) amplified GABAergic currents in a subset of ipRGCs. Furthermore, this D1R-mediated facilitation of the GABA conductance in ipRGCs was mediated by a cAMP/PKA-dependent mechanism. Taken together, these findings reinforce the idea that dopamine’s modulatory role in retinal adaptation affects both non-image forming as well as image forming visual functions.


  • Open Access

    µ-Opioid Receptors Expressed by Intrinsically Photosensitive Retinal Ganglion Cells Contribute to Morphine-Induced Behavioral Sensitization

    by Nikolas Bergum, Casey-Tyler Berezin, Connie M. King, Jozsef Vigh

    Opioid drugs are the most effective tools for treating moderate to severe pain. Despite their analgesic efficacy, long-term opioid use can lead to drug tolerance, addiction, and sleep/wake disturbances. While the link between opioids and sleep/wake problems is well-documented, the mechanism underlying opioid-related sleep/wake problems remains largely unresolved. Importantly, intrinsically photosensitive retinal ganglion cells (ipRGCs), the cells that transmit environmental light/dark information to the brain’s sleep/circadian centers to regulate sleep/wake behavior, express μ-opioid receptors (MORs). In this study, we explored the potential contribution of ipRGCs to opioid-related sleep/circadian disruptions. Using implanted telemetry transmitters, we measured changes in horizontal locomotor activity and body temperature in mice over the course of a chronic morphine paradigm. Mice lacking MORs expressed by ipRGCs (McKO) exhibited reduced morphine-induced behavioral activation/sensitization compared with control littermates with normal patterns of MOR expression. Contrastingly, mice lacking MORs globally (MKO) did not acquire morphine-induced locomotor activation/sensitization. Control mice also showed morphine-induced hypothermia in both the light and dark phases, while McKO littermates only exhibited morphine-induced hypothermia in the dark. Interestingly, only control animals appeared to acquire tolerance to morphine’s hypothermic effect. Morphine, however, did not acutely decrease the body temperature of MKO mice. These findings support the idea that MORs expressed by ipRGCs could contribute to opioid-related sleep/wake problems and thermoregulatory changes.


  • Open Access

    Morphine Accumulates in the Retina Following Chronic Systemic Administration

    by Nikolas Bergum, Casey-Tyler Berezin, Gregory Dooley, Jozsef Vigh

    Opioid transport into the central nervous system is crucial for the analgesic efficacy of opioid drugs. Thus, the pharmacokinetics of opioid analgesics such as morphine have been extensively studied in systemic circulation and the brain. While opioid metabolites are routinely detected in the vitreous fluid of the eye during postmortem toxicological analyses, the pharmacokinetics of morphine within the retina of the eye remains largely unexplored. In this study, we measured morphine in mouse retina following systemic exposure. We showed that morphine deposits and persists in the retina long after levels have dropped in the serum. Moreover, we found that morphine concentrations (ng/mg tissue) in the retina exceeded brain morphine concentrations at all time points tested. Perhaps most intriguingly, these data indicate that following chronic systemic exposure, morphine accumulates in the retina, but not in the brain or serum. These results suggest that morphine can accumulate in the retina following chronic use, which could contribute to the deleterious effects of chronic opioid use on both image-forming and non-image-forming visual functions.